Difference between revisions of "Obinutuzumab (GA101)"
(Created page with "'''In clinical trials'''. Also known as RO5072759, Afutuzumab. ==General information== Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody. Engineered...") |
m |
||
Line 2: | Line 2: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody. Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region which is postulated to enhance its immunomodulatory effect.<ref>Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011 Jan-Feb;3(1):76-99. Epub 2011 Jan 1. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038014/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21051951 PubMed]</ref> | + | Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody. Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region, which is postulated to enhance its immunomodulatory effect.<ref>Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011 Jan-Feb;3(1):76-99. Epub 2011 Jan 1. [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038014/ link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/21051951 PubMed]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information |
Revision as of 04:58, 22 February 2012
In clinical trials. Also known as RO5072759, Afutuzumab.
General information
Class/mechanism: Glyco-engineered anti-CD20 IgG1 type II monoclonal antibody. Engineered with a modified elbow hinge residue (valine instead of leucine at Kabat position 11) and a glyco-engineered Fc region, which is postulated to enhance its immunomodulatory effect.[1]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
No information available.
References
- ↑ Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011 Jan-Feb;3(1):76-99. Epub 2011 Jan 1. link to original article PubMed